drugset / Trial / NCT02985216

Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

NCT02985216

Phase 3 Completed 371 enrolled Yuhan Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-blind, Active-Controlled, Multi-center, Phase 3 Trial to Compare the Safety and Efficacy between YHD1119 and Pregabalin in Patients with Peripheral Neuropathic Pain

Timeline

Start
2017-02-07
Primary completion
2018-04-27
Completion
2018-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg Oral
Subject Pregabalin Small molecule 150 mg Oral
Subject Pregabalin Small molecule 300 mg Oral
Subject Pregabalin Small molecule 600 mg Oral

Indications